- Home
- ENSC vs TOVX Comparison
ENSC vs TOVX Comparison
Compare ENSC & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSC
- TOVX
- Stock Information
- Founded
- ENSC 2003
- TOVX 2001
- Country
- ENSC United States
- TOVX United States
- Employees
- ENSC N/A
- TOVX N/A
- Industry
- ENSC Biotechnology: Pharmaceutical Preparations
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- ENSC Health Care
- TOVX Health Care
- Exchange
- ENSC Nasdaq
- TOVX Nasdaq
- Market Cap
- ENSC 3.4M
- TOVX 3.8M
- IPO Year
- ENSC N/A
- TOVX 2006
- Fundamental
- Price
- ENSC $2.38
- TOVX $0.47
- Analyst Decision
- ENSC
- TOVX Hold
- Analyst Count
- ENSC 0
- TOVX 1
- Target Price
- ENSC N/A
- TOVX N/A
- AVG Volume (30 Days)
- ENSC 455.1K
- TOVX 1.8M
- Earning Date
- ENSC 05-13-2025
- TOVX 05-14-2025
- Dividend Yield
- ENSC N/A
- TOVX N/A
- EPS Growth
- ENSC N/A
- TOVX N/A
- EPS
- ENSC N/A
- TOVX N/A
- Revenue
- ENSC $6,224,081.00
- TOVX N/A
- Revenue This Year
- ENSC N/A
- TOVX N/A
- Revenue Next Year
- ENSC $1,381.48
- TOVX N/A
- P/E Ratio
- ENSC N/A
- TOVX N/A
- Revenue Growth
- ENSC 256.35
- TOVX N/A
- 52 Week Low
- ENSC $1.62
- TOVX $0.40
- 52 Week High
- ENSC $14.67
- TOVX $7.37
- Technical
- Relative Strength Index (RSI)
- ENSC 49.99
- TOVX 29.91
- Support Level
- ENSC $2.12
- TOVX $0.43
- Resistance Level
- ENSC $2.57
- TOVX $0.54
- Average True Range (ATR)
- ENSC 0.21
- TOVX 0.05
- MACD
- ENSC 0.04
- TOVX 0.03
- Stochastic Oscillator
- ENSC 53.87
- TOVX 41.18
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.